Company & Sponsor Intelligence
Neurothera Labs Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting2
Completed0
Countries3
Therapeutic footprint
autismneurodevelopmental_other
Indexed studies
NCT03651726A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome
neurodevelopmental_other · GermanyPHASE2
neurodevelopmental_other · GermanyPHASE2
NCT05182697SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
autism · IsraelNA
autism · IsraelNA
NCT05126888SCI-110 in the Treatment of Tourette Syndrome
neurodevelopmental_other · United StatesPHASE2
neurodevelopmental_other · United StatesPHASE2
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →